TBF Tissue Engineering Celebrates 20 Years of Clinical Use of the PHOENIX Cancellous Bone Treatment

Aug. 29, 2012 - PRLog -- Mions,  Lyon-Rhone-Alpes Biocluster, France

TBF Tissue Engineering (http://www.tbf-lab.com), a leading provider of orthopedic cancellous bone allografts from live donors only, is celebrating 20 years of sterilizing human allografts through the PHOENIX® process. Since the first clinical use in 1992, there has been no incidence of allograft associated infections from more than the 100,000 grafts implanted.

The PHOENIX® process is a highly advanced technical cleaning process designed and developed by TBF Tissue Engineering, France, to sterilize and preserve bone tissue for implantation. The end-product is secured, freeze-dried and packaged for a 5-yr shelf life storage at room temperature. PHOENIX® Products has been duely authorized by the Affsaps/ANMS (the French MOH authorities) and is fully compliant with most restrictive European directives on Tissues.
The cancellous bone allografts produced through the PHOENIX® Process are used in dental, orthopedic, spinal, neuro, trauma and oncology surgery.

“Besides, the ethical foundations of working only with live donors, we are extremely proud of our history of PHOENIX®-secured implants, which fully meet our mission statement, ie. guarantee patients and surgeons utmost quality products with maximum safety.” said Dr. Laurence BARNOUIN, General Manager of TBF. “Providing efficient, easy to use and safe products is indeed a top priority for our company.”